Role of Cyclin Dependent Kinase Inhibitors as Anticancer Drug in Present Medicinal System
Keywords:
CDK, Cancer, Enzyme etc.Abstract
A group of disease which includes uncontrolled cell division is known as cancer. It has the capacity to spread from one part to another part of the body. So the uncontrolled cell division is the major cause of cancer. Normally the cell cycle division is regulated by Cyclin-Dependent Kinases. Cyclin-Dependent Kinases belong to the kinases family, which mainly regulate the cell cycle by the transfer of phosphate groups.
References
1. Ali, I., Wani, W.A. and Saleem, K. (2011) ‘Cancer scenario in India with future perspectives”, Cancer Therapy, 8, pp. 56-70.
2. Brazidec, J.Y.L., Pasis, A., Tam, B., Boykin, C., Black, C., Wang, D., Claassen, G., Chong, C.H., Chao, J., Fan, J., Nguyen, K., Silvian, L., Ling, L., Zhang, L., Choi, M., Teng, M., Pathan, N., Zhao, S., Li, T. and Taveras, A. (2012) ‘Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d] pyrimidines as dual inhibitors of Aurora kinases and CDK1’, Bioorganic & Medicinal Chemistry Letters ,22, pp. 2070–2074.
3. Cancer (2015) Available at: http://www.who.int/mediacentre/factsheets/fs297 / en/ (Accessed: 19-05-2015).
4. Cancer (2015) Available at: https://en.wikipedia.org/wiki/Cancer (Accessed: 15-05-2015).
5. Chorawala, M.R., Oza, P.M. and Shah, G.B. (2012) ‘Mechanisms of anticancer drug resistance’, International Journal of Pharmaceutical Sciences and Drug Research, 4(1), pp. 1-9,
6. Finn, P.W. and Kavraki, L.E. (1999) ‘Computational approaches to drug design’, Algorithmica, 25 (2), pp. 347-371.
7. “Genes and Cancer”, American Cancer Society, pp. 1-10, 2014.
8. Gottesman, M.M. (2002) ‘Mechanism of anticancer drug resistance’, Annual Review of Medicine, 53, pp. 615-627
9. Horiuchi, T., Nagata, M., Kitagawa, M., Akahane, K., and Uoto, K. (2009) ‘Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation and structure–activity relationships. Part 2’, Bioorganic & Medicinal Chemistry, 17, pp. 7850–7860.
10. Ibrahim, D.A., and Ismail, N.S.M. (2011) ‘Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors’, European Journal of Medicinal Chemistry, 46, pp. 5825e5832.
11. Jaramillo, C., Diego, E.D., Hamdouchi, C., Collins, E., Keyser, H., Sa´nchez-Martinez, C., Prado, M.D., Norman, B., Brooks, H.B., Watkins, S.A., Spencer, C.D., Dempsey, J.A., Anderson, B.D., Anderson, R.M., Leggett, T., Patel, B., Schultz, R.M., Espinosa, J., Vieth, M., Zhang, F., and Timm, D.E. (2004) ‘Aminoimidazo[1,2 a] pyridines as a new structural class ofcyclin-dependent kinase inhibitors. Part 1: Design, synthesis and biological evaluation’ Bioorganic & Medicinal Chemistry Letters ,14, pp., 6095–6099.
12. Malumbres, M. and Barbacid, M. (2005) ‘Mammalian cyclin-dependent kinases’, Trends in Biochemical Sciences, 30(11), pp. 630-641.
13. Martínez, C.S., Gelbert, L.M., Lallena, M.J. and Dios, A.D. 2015 ‘Cyclin dependent kinase (CDK) inhibitors as anticancer drugs’, Bioorganic & Medicinal Chemistry Letters, 25, pp. 3420–3435.
14. Massuard, M.C.V., Baltus, C.B., Jorda, R., Marot, C., Berka, K., Bazgier, V., Krystof, V. and Pri_e, G. (2016) ‘Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/ Cyclin E inhibitors’, European Journal of Medicinal Chemistry, 108, pp. 701-719.
15. Murthy, N.S., Chaudhary, K. and Rath G.K. (2008) ‘Burden of cancerand projections for 2016, Indian scenario: Gaps in the availability of radiotherapy treatment facilities’, Asian Pacific Journal of Cancer Prevention, 9, pp. 671-677.
16. Panno, J. (2005) Cancer: The role of genes , lifestyle & environment. [Online]. Available at: http://ebookdb.info/download/0816049505/ Cancer%3A+The+ Role+of +Genes%2C+ Lifestyle%2C+and+Environment +%28New +Biology % 29/ (Accessed: 15 May 2016).
17. Pevarello, P., Fancelli, D., Vulpetti, A., Amici, R., Villa, M., Pittala, V., Vianello, P., Cameron, A., Ciomei, M., Mercurio, C., Mercurio, J.R., Roletto, F., Varasi, M., and Brasca, M.G. (2006) ‘3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors’, Bioorganic & Medicinal Chemistry Letters, 16, pp. 1084–1090.
18. Singh, S.K., Tripathi, S.K., Dessalew, N. and Singh, P. (2012) ‘Cyclin Dependent Kinase as significant target of cancer treatment’, Current Cancer Therapy Reviews, 8, pp. 225-235.
19. Tripathi, K.D. Essentials of Medical Pharmacology. 6th edn. New Delhi Jaypee Brothers Medical Publishers (P) LTD.
20. Wang, S., Shao, H., Shi, S., Foley, D.W., Lam, F., Abbas, A.Y., Liu, X., Huang, S., Jiang, X., Baharin, N. & Fischer, P.M. (2013) ‘Synthesis, structureeactivity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents’, European Journal of Medicinal Chemistry, 70, pp. 447-455.
21. Wang, S., Shao, H., Shi, S., Huang, S., Hole, A.S., Abbas, A.Y., Baumli, S., Liu, X., Lam, F., Foley, D.W., Fischer, P.M., Noble, M., Endicott, J.A. and Pepper, C. (2013) ‘Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure?Activity Relationship, and Anticancer Activities’, Journal of Medicinal Chemistry, 56, pp. 640-659.
22. Zhu, H.L., Sun, J., Lv, X.H., Qiu, H.Y., Wang, Y.T., Du, Q.R., Li, D.D. and Yang, Y.H. (2013) ‘Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors’, European Journal of Medicinal Chemistry, 68, pp. 1-9.
********
2. Brazidec, J.Y.L., Pasis, A., Tam, B., Boykin, C., Black, C., Wang, D., Claassen, G., Chong, C.H., Chao, J., Fan, J., Nguyen, K., Silvian, L., Ling, L., Zhang, L., Choi, M., Teng, M., Pathan, N., Zhao, S., Li, T. and Taveras, A. (2012) ‘Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d] pyrimidines as dual inhibitors of Aurora kinases and CDK1’, Bioorganic & Medicinal Chemistry Letters ,22, pp. 2070–2074.
3. Cancer (2015) Available at: http://www.who.int/mediacentre/factsheets/fs297 / en/ (Accessed: 19-05-2015).
4. Cancer (2015) Available at: https://en.wikipedia.org/wiki/Cancer (Accessed: 15-05-2015).
5. Chorawala, M.R., Oza, P.M. and Shah, G.B. (2012) ‘Mechanisms of anticancer drug resistance’, International Journal of Pharmaceutical Sciences and Drug Research, 4(1), pp. 1-9,
6. Finn, P.W. and Kavraki, L.E. (1999) ‘Computational approaches to drug design’, Algorithmica, 25 (2), pp. 347-371.
7. “Genes and Cancer”, American Cancer Society, pp. 1-10, 2014.
8. Gottesman, M.M. (2002) ‘Mechanism of anticancer drug resistance’, Annual Review of Medicine, 53, pp. 615-627
9. Horiuchi, T., Nagata, M., Kitagawa, M., Akahane, K., and Uoto, K. (2009) ‘Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation and structure–activity relationships. Part 2’, Bioorganic & Medicinal Chemistry, 17, pp. 7850–7860.
10. Ibrahim, D.A., and Ismail, N.S.M. (2011) ‘Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors’, European Journal of Medicinal Chemistry, 46, pp. 5825e5832.
11. Jaramillo, C., Diego, E.D., Hamdouchi, C., Collins, E., Keyser, H., Sa´nchez-Martinez, C., Prado, M.D., Norman, B., Brooks, H.B., Watkins, S.A., Spencer, C.D., Dempsey, J.A., Anderson, B.D., Anderson, R.M., Leggett, T., Patel, B., Schultz, R.M., Espinosa, J., Vieth, M., Zhang, F., and Timm, D.E. (2004) ‘Aminoimidazo[1,2 a] pyridines as a new structural class ofcyclin-dependent kinase inhibitors. Part 1: Design, synthesis and biological evaluation’ Bioorganic & Medicinal Chemistry Letters ,14, pp., 6095–6099.
12. Malumbres, M. and Barbacid, M. (2005) ‘Mammalian cyclin-dependent kinases’, Trends in Biochemical Sciences, 30(11), pp. 630-641.
13. Martínez, C.S., Gelbert, L.M., Lallena, M.J. and Dios, A.D. 2015 ‘Cyclin dependent kinase (CDK) inhibitors as anticancer drugs’, Bioorganic & Medicinal Chemistry Letters, 25, pp. 3420–3435.
14. Massuard, M.C.V., Baltus, C.B., Jorda, R., Marot, C., Berka, K., Bazgier, V., Krystof, V. and Pri_e, G. (2016) ‘Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/ Cyclin E inhibitors’, European Journal of Medicinal Chemistry, 108, pp. 701-719.
15. Murthy, N.S., Chaudhary, K. and Rath G.K. (2008) ‘Burden of cancerand projections for 2016, Indian scenario: Gaps in the availability of radiotherapy treatment facilities’, Asian Pacific Journal of Cancer Prevention, 9, pp. 671-677.
16. Panno, J. (2005) Cancer: The role of genes , lifestyle & environment. [Online]. Available at: http://ebookdb.info/download/0816049505/ Cancer%3A+The+ Role+of +Genes%2C+ Lifestyle%2C+and+Environment +%28New +Biology % 29/ (Accessed: 15 May 2016).
17. Pevarello, P., Fancelli, D., Vulpetti, A., Amici, R., Villa, M., Pittala, V., Vianello, P., Cameron, A., Ciomei, M., Mercurio, C., Mercurio, J.R., Roletto, F., Varasi, M., and Brasca, M.G. (2006) ‘3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors’, Bioorganic & Medicinal Chemistry Letters, 16, pp. 1084–1090.
18. Singh, S.K., Tripathi, S.K., Dessalew, N. and Singh, P. (2012) ‘Cyclin Dependent Kinase as significant target of cancer treatment’, Current Cancer Therapy Reviews, 8, pp. 225-235.
19. Tripathi, K.D. Essentials of Medical Pharmacology. 6th edn. New Delhi Jaypee Brothers Medical Publishers (P) LTD.
20. Wang, S., Shao, H., Shi, S., Foley, D.W., Lam, F., Abbas, A.Y., Liu, X., Huang, S., Jiang, X., Baharin, N. & Fischer, P.M. (2013) ‘Synthesis, structureeactivity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents’, European Journal of Medicinal Chemistry, 70, pp. 447-455.
21. Wang, S., Shao, H., Shi, S., Huang, S., Hole, A.S., Abbas, A.Y., Baumli, S., Liu, X., Lam, F., Foley, D.W., Fischer, P.M., Noble, M., Endicott, J.A. and Pepper, C. (2013) ‘Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure?Activity Relationship, and Anticancer Activities’, Journal of Medicinal Chemistry, 56, pp. 640-659.
22. Zhu, H.L., Sun, J., Lv, X.H., Qiu, H.Y., Wang, Y.T., Du, Q.R., Li, D.D. and Yang, Y.H. (2013) ‘Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors’, European Journal of Medicinal Chemistry, 68, pp. 1-9.
********
Downloads
Published
2021-04-05
How to Cite
Sharma, D. ., & Kumar, D. P. (2021). Role of Cyclin Dependent Kinase Inhibitors as Anticancer Drug in Present Medicinal System. International Journal of Multidisciplinary Research Education Analysis and Development- IJMREAD, 01–07. Retrieved from https://ijmread.com/index.php/ijmread/article/view/23
Issue
Section
Articles
License
Copyright (c) 2021 Deepanshu Sharma, Dr Pramod Kumar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
